TMO THERMO FISHER SCIENTIFIC INC.

Price Chart

Executive Summary

HSBC double-downgraded Thermo Fisher Scientific (TMO) from Buy to Hold on June 3, slashing its price target by 19.4% to $540 from $670. The call is a sharp contrarian move against a consensus that remains 85% Buy-rated (29 of 34 analysts at Buy or Strong Buy). TMO currently trades at $482.08, implying a 13.4% upside to the new HSBC target but a 12% discount to the consensus mean of $611.56. HSBC's accuracy on TMO is 67% (2 of 3 calls) with a negative average return of -0.4%, ranking it below top-tier firms like Baird (83% on 6 calls) and Barclays (80% on 10 calls). The downgrade is the only negative analyst action in the past 30 days, with zero upgrades and one downgrade. EPS revisions are mixed: the current quarter saw 12 downward revisions in 30 days, while the next quarter (+1q) saw 14 upward revisions, suggesting near-term headwinds but a potential rebound. Insider selling is present but not alarming — two sales totaling ~$1M in March-April, with no buys. Institutional buying is strong, with FMR LLC adding 29% and Bank of America adding 34.9%. The bottom line: HSBC's downgrade is a minority view from a mediocre-accuracy firm, but the large PT cut and the double-downgrade signal warrant caution against the overwhelmingly bullish consensus.

Impact Score

Consensus & Targets

Consensus is heavily bullish: 11 Strong Buy, 18 Buy, 5 Hold, 0 Sell, 0 Strong Sell — 85% Buy/Strong Buy (29 of 34 analysts). HSBC's Hold is a clear outlier against this consensus direction.

Mean PT is $611.56, median $615, high $750, low $490. Current price $482.08 implies 26.9% upside to the mean. HSBC's $540 target is 12% below the mean and just above the low end, making it one of the most bearish on the Street.

Recent Analyst Activity

30-day analyst activity: 0 upgrades, 1 downgrade (HSBC). EPS revisions show near-term caution: current quarter had 12 downward revisions vs 2 upward in 30 days, but next quarter (+1q) had 14 upward vs 3 downward, suggesting a potential inflection. Full-year 2026 estimates are stable (2 up, 0 down in 30 days).

Firm Track Record — HSBC

HSBC accuracy: 55% on 263 calls | avg return: 5.5%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

HSBC has a 67% accuracy rate on 3 TMO calls with a negative average return of -0.4%, placing it in the 'top tier' vs. average but below top performers like Baird (83% on 6 calls, +10.5% avg return) and Barclays (80% on 10 calls, +8.5% avg return). The best firm on TMO is Argus Research (100% on 2 calls, +9.5% avg return); the worst is Morgan Stanley (20% on 5 calls, -13.7% avg return).

Earnings Estimates

Next earnings: Jul 21, 2026

Cross-Platform Signals

Insider trades: two sells totaling ~$1M (Pettiti $185K, Shafer $803K) in March-April 2026 — no buys. Congressional activity: one sell (Dwight Evans, $1K-$15K) and two buys (Ro Khanna, $16K-$65K combined) — mixed. Institutional changes: strongly positive — FMR LLC added 29% ($5.7B), Norges Bank new position ($3.1B), Bank of America added 34.9% ($2.6B). Short interest is elevated at 62% short ratio (893,621 shares short vs 1.44M TRF volume), indicating bearish positioning. The analyst downgrade aligns with short interest and insider selling but diverges from institutional buying.

Documents Analyzed

Report based on filing metadata.

US Market Status